Smooth muscle cells, rather than macrophages, appear to be the major source of lipoprotein lipase in the human vascular wall, though its synthesis may be down-regulated in atherosclerotic plaques.
Shifts research focus from macrophages to smooth muscle cells as LPL source; leaves open functional role in human atherosclerosis.
The localization of lipoprotein lipase (LPL) in human atherosclerotic lesions was studied with immunocytochemical techniques. In the fibrous cap and surrounding intima of the plaque, where the smooth muscle cell is the dominating cell type, a high number of cells reacted with anti-LPL. A much lower number of stained cells was seen in the central lipid core region where the macrophages dominate. Further characterization of the LPL-containing cells in tissue sections showed that most of them were smooth muscle cells. Only a minor fraction of the macrophages in the plaque contained the enzyme. The results were confirmed on isolated cells from atherosclerotic tissue. Lipoprotein lipase was also detected in smooth muscle cells of non-atherosclerotic arteries. These findings suggest that the smooth muscle cells are the major source of LPL in the vascular wall. However, the enzyme was not present in some of the smooth muscle cells in the atherosclerotic lesion. This may imply that LPL synthesis is down-regulated in the atherosclerotic plaque.
No takes yet. Share an insight, caveat, or question.
Jonasson et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: